sarafloxacin has been researched along with norfloxacin in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (71.43) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouzard, D; Di Cesare, P; Essiz, M; Jacquet, JP; Masuyoshi, M; Oki, T; Remuzon, P; Weber, A | 1 |
| Chu, DT; Claiborne, AK; Fernandes, PB; Maleczka, RE; Nordeen, CW; Pernet, AG; Pihuleac, E | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Chen, L; Fan, L; He, ZQ; Jiang, L; Lei, HS; Liu, CP; Liu, J; Peng, XM; Xu, XR; Yang, DC; Zhou, CH; Zhou, FW; Zou, YY | 1 |
| Ayers, LW; Barry, AL; Gavan, TL; Gerlach, EH; Jones, RN; Thornsberry, C | 1 |
| Smith, SM | 1 |
| Barry, AL; Jones, RN; Thornsberry, C | 1 |
| Bailer, R; Chu, DT; Fernandes, PB; Hanson, CW; Stamm, JM; Vojtko, C | 1 |
| Liu, S; Meyer, RD | 1 |
| Ballard, RC; Fehler, G; Koornhof, HJ; Liebowitz, LD; Saunders, J | 1 |
| Berlin, OG; Bruckner, DA; Young, LS | 1 |
| Habiyaremye, I; Vandepitte, J; Verbist, L | 1 |
| Verbist, L | 1 |
| Deforges, L; Duval, J; Le Van Thoi, J; Soussy, CJ | 1 |
| King, A; Phillips, I | 1 |
| Bower, RR; Chu, DT; Fernandes, PB; Jarvis, KP; Ramer, NR; Shipkowitz, N | 1 |
| Donato, JB; Joseph, WS; LeFrock, JL; Smith, BR; Weber, SJ | 1 |
| Holzgrabe, U; Kiefer, W; Neugebauer, U; Popp, J; Schmitt, M; Szeghalmi, A | 1 |
| Chen, X; Hua, H; Ji, C; Lin, X; Liu, Y; Tang, S; Yue, Z | 1 |
| Companyó, R; Guiteras, J; Jiménez, V | 1 |
| Kang, H; Lin, L; Luo, Y; Tu, X; Wu, W; Xie, L; Yue, Z; Zhang, Y | 1 |
21 other study(ies) available for sarafloxacin and norfloxacin
| Article | Year |
|---|---|
Fluoronaphthyridines and quinolones as antibacterial agents. 1. Synthesis and structure-activity relationships of new 1-substituted derivatives.
Topics: 4-Quinolones; Animals; Anti-Bacterial Agents; Chemical Phenomena; Chemistry; Dogs; Gram-Negative Bacteria; Mice; Microbial Sensitivity Tests; Molecular Structure; Naphthyridines; Staphylococcus; Structure-Activity Relationship | 1989 |
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.
Topics: Acinetobacter; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Chemical Phenomena; Chemistry; Ciprofloxacin; Enterobacter; Escherichia coli; Female; Fluorine; Fluoroquinolones; Klebsiella pneumoniae; Mice; Norfloxacin; Pefloxacin; Piperazines; Pseudomonas aeruginosa; Quinolines; Staphylococcus; Streptococcus; Structure-Activity Relationship | 1985 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
Topics: Antitubercular Agents; Artemisinins; Drug Design; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship | 2014 |
In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility tests.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Enterobacteriaceae; Fluoroquinolones; Gram-Negative Bacteria; Microbial Sensitivity Tests; Norfloxacin; Piperazines; Quinolines; Staphylococcus; Streptococcus | 1986 |
In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Enoxacin; Fluoroquinolones; Humans; Methicillin; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Penicillin Resistance; Piperazines; Quinolines; Staphylococcus aureus | 1986 |
In vitro evaluation of A-56619 and A-56620, two new quinolones.
Topics: Anti-Bacterial Agents; Bacteria; Bacteria, Anaerobic; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Fluoroquinolones; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Piperazines; Quinolines | 1986 |
In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Topics: Anti-Infective Agents; Aztreonam; Bacteria; Cefotaxime; Ciprofloxacin; Drug Combinations; Enterobacteriaceae; Escherichia coli; Fluoroquinolones; Gentamicins; Haemophilus influenzae; Half-Life; Humans; Imipenem; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Norfloxacin; Penicillins; Piperacillin; Piperazines; Pseudomonas aeruginosa; Quinolines; Staphylococcus aureus; Streptococcus; Thienamycins | 1986 |
In vitro activity of aryl fluoroquinolones, Abbott 56619 and Abbott 56620, compared to ciprofloxacin, norfloxacin and beta-lactams versus multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Microbial Sensitivity Tests; Norfloxacin; Pseudomonas aeruginosa | 1986 |
In vitro activity of A-56619 (difloxacin), A-56620, and other new quinolone antimicrobial agents against genital pathogens.
Topics: Anti-Bacterial Agents; Chlamydia trachomatis; Ciprofloxacin; Female; Fluoroquinolones; Gardnerella vaginalis; Genitalia; Haemophilus; Haemophilus ducreyi; Humans; Male; Microbial Sensitivity Tests; Mycoplasma; Neisseria gonorrhoeae; Norfloxacin; Ofloxacin; Oxazines; Ureaplasma | 1986 |
In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Microbial; Enoxacin; Fluoroquinolones; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Quinolines | 1987 |
[Comparative in vitro activity of 10 new 4-quinolones against enteropathogenic bacteria].
Topics: Anti-Bacterial Agents; Campylobacter fetus; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines; Salmonella; Shigella; Vibrio cholerae; Yersinia enterocolitica | 1987 |
Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Gram-Negative Bacteria; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines | 1987 |
[In vitro antibacterial activity of 2 new quinolones: A 56619 (difloxacin) and A 56620. Comparison with pefloxacin, ofloxacin and ciprofloxacin].
Topics: Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Fluoroquinolones; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin | 1987 |
The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
Topics: Acinetobacter; Aeromonas; Anti-Bacterial Agents; Bacteria; Bacteria, Anaerobic; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Fluoroquinolones; Gram-Positive Bacteria; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Pefloxacin; Quinolines | 1986 |
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enterobacteriaceae Infections; Escherichia coli Infections; Female; Fluoroquinolones; Half-Life; Immunosuppression Therapy; Klebsiella Infections; Mice; Norfloxacin; Piperazines; Proteus Infections; Pseudomonas Infections; Pyelonephritis; Quinolines; Salmonella Infections, Animal; Staphylococcal Infections; Streptococcal Infections | 1986 |
In vitro activity of A-56619 and A56620, two new aryl-fluoroquinolone antimicrobial agents.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Enterobacteriaceae; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Norfloxacin; Piperazines; Quinolines | 1986 |
Vibrational spectroscopic characterization of fluoroquinolones.
Topics: Aza Compounds; Cinoxacin; Ciprofloxacin; DNA Gyrase; DNA, Bacterial; Enoxacin; Enzyme Inhibitors; Fluoroquinolones; Hydrogen Bonding; Hydrogen-Ion Concentration; Models, Chemical; Models, Molecular; Models, Theoretical; Moxifloxacin; Nalidixic Acid; Norfloxacin; Ofloxacin; Oxolinic Acid; Quinolines; Quinolones; Spectrophotometry, Infrared; Spectrum Analysis, Raman; Temperature; Ultraviolet Rays; Vibration; Water | 2005 |
[Determination of 16 quinolone residues in animal tissues using high performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry].
Topics: Animals; Chromatography, High Pressure Liquid; Ciprofloxacin; Enoxacin; Enrofloxacin; Fluoroquinolones; Norfloxacin; Ofloxacin; Pefloxacin; Quinolones; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization | 2007 |
Analysis of quinolone antibiotics in eggs: preparation and characterization of a raw material for method validation and quality control.
Topics: Anti-Bacterial Agents; Chromatography, Liquid; Ciprofloxacin; Eggs; Enrofloxacin; Fluoroquinolones; Food Contamination; Norfloxacin; Oxolinic Acid; Quality Control; Quinolones; Reproducibility of Results | 2012 |
[Determination of 25 quinolones in cosmetics by liquid chromatography-tandem mass spectrometry].
Topics: Chromatography, Liquid; Ciprofloxacin; Cosmetics; Drug Residues; Enrofloxacin; Fluoroquinolones; Hexanes; Norfloxacin; Ofloxacin; Quinolones; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2015 |